$4.580
+0.231 (+5.05%)收盘时
- High
- 4.690
- Open
- 4.360
- VWAP
- 4.53
- Vol
- 35.59K
- Mkt Cap
- 7.45M
- Low
- 4.330
- Amount
- 161.33K
- EV/EBITDA, TTM
- 0.00
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
Analyst Ratings (2)
估值指标
事件时间线
资讯
3.501-06NASDAQ.COMLucid, Nuro, and Uber Unveil Global Robotaxi Production-Intent Vehicles
- 3.501-05PRnewswire
Lucid, Uber, and Nuro Unveil Production Intent Robotaxi at CES 2026
3.501-05NewsfilterLucid, Nuro, and Uber Unveil 2026 Robotaxi Production Intent Vehicles
8.505-02NewsfilterelectroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
7.001-07PRnewswireSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders
NURO FAQ — answered by Alphio AI
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
2 analysts cover NURO: 1 rate it Buy, 1 Hold and 0 Sell.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。